IRIS Accounts Production v24.2.0.383 09433053 director 1.5.23 30.4.24 30.4.24 0 0 true false true false false true false Ordinary A 1.00000 Ordinary B 1.00000 iso4217:GBPiso4217:USDiso4217:EURxbrli:sharesxbrli:pureutr:tonnesutr:kWh094330532023-04-30094330532024-04-30094330532023-05-012024-04-30094330532022-04-30094330532022-05-012023-04-30094330532023-04-3009433053ns15:EnglandWales2023-05-012024-04-3009433053ns14:PoundSterling2023-05-012024-04-3009433053ns10:Director12023-05-012024-04-3009433053ns10:PrivateLimitedCompanyLtd2023-05-012024-04-3009433053ns10:SmallEntities2023-05-012024-04-3009433053ns10:AuditExempt-NoAccountantsReport2023-05-012024-04-3009433053ns10:SmallCompaniesRegimeForDirectorsReport2023-05-012024-04-3009433053ns10:SmallCompaniesRegimeForAccounts2023-05-012024-04-3009433053ns10:FullAccounts2023-05-012024-04-3009433053ns10:OrdinaryShareClass12023-05-012024-04-3009433053ns10:OrdinaryShareClass22023-05-012024-04-3009433053ns10:RegisteredOffice2023-05-012024-04-3009433053ns5:CurrentFinancialInstruments2024-04-3009433053ns5:CurrentFinancialInstruments2023-04-3009433053ns5:Non-currentFinancialInstruments2024-04-3009433053ns5:Non-currentFinancialInstruments2023-04-3009433053ns5:ShareCapital2024-04-3009433053ns5:ShareCapital2023-04-3009433053ns5:RetainedEarningsAccumulatedLosses2024-04-3009433053ns5:RetainedEarningsAccumulatedLosses2023-04-3009433053ns5:CostValuation2023-04-3009433053ns5:Subsidiary12023-05-012024-04-3009433053ns5:Subsidiary112023-05-012024-04-3009433053ns5:Subsidiary12024-04-3009433053ns5:Subsidiary12023-04-3009433053ns5:Subsidiary12022-05-012023-04-3009433053ns5:CurrentFinancialInstrumentsns5:WithinOneYear2024-04-3009433053ns5:CurrentFinancialInstrumentsns5:WithinOneYear2023-04-3009433053ns5:Non-currentFinancialInstrumentsns5:BetweenOneTwoYears2024-04-3009433053ns5:Non-currentFinancialInstrumentsns5:BetweenOneTwoYears2023-04-3009433053ns5:Non-currentFinancialInstrumentsns5:BetweenTwoFiveYears2024-04-3009433053ns5:Non-currentFinancialInstrumentsns5:BetweenTwoFiveYears2023-04-3009433053ns5:Secured2024-04-3009433053ns5:Secured2023-04-3009433053ns10:OrdinaryShareClass12024-04-3009433053ns10:OrdinaryShareClass22024-04-3009433053ns5:RetainedEarningsAccumulatedLosses2023-04-3009433053ns5:RetainedEarningsAccumulatedLosses2023-05-012024-04-30
REGISTERED NUMBER: 09433053 (England and Wales)



















Unaudited Financial Statements

for the Year Ended 30 April 2024

for

NOVA HEALTH (HOLDINGS) LTD

NOVA HEALTH (HOLDINGS) LTD (REGISTERED NUMBER: 09433053)






Contents of the Financial Statements
for the Year Ended 30 April 2024




Page

Company Information 1

Statement of Financial Position 2

Notes to the Financial Statements 4


NOVA HEALTH (HOLDINGS) LTD

Company Information
for the Year Ended 30 April 2024







DIRECTOR: Yasirali Pirmohamed





REGISTERED OFFICE: Moir Pharmacy
Regent Street
Long Eaton
Nottingham
Nottinghamshire
NG10 1JX





REGISTERED NUMBER: 09433053 (England and Wales)





ACCOUNTANTS: Brindleys Limited
2 Wheeleys Road
Edgbaston
Birmingham
West Midlands
B15 2LD

NOVA HEALTH (HOLDINGS) LTD (REGISTERED NUMBER: 09433053)

Statement of Financial Position
30 April 2024

2024 2023
Notes £    £    £    £   
FIXED ASSETS
Investments 4 622,916 622,916

CURRENT ASSETS
Cash at bank and in hand 68 1

CREDITORS
Amounts falling due within one year 5 278,370 260,471
NET CURRENT LIABILITIES (278,302 ) (260,470 )
TOTAL ASSETS LESS CURRENT
LIABILITIES

344,614

362,446

CREDITORS
Amounts falling due after more than one year 6 248,975 285,323
NET ASSETS 95,639 77,123

CAPITAL AND RESERVES
Called up share capital 9 2 2
Retained earnings 10 95,637 77,121
SHAREHOLDERS' FUNDS 95,639 77,123

The company is entitled to exemption from audit under Section 477 of the Companies Act 2006 for the year ended 30 April 2024.

The members have not required the company to obtain an audit of its financial statements for the year ended 30 April 2024 in accordance with Section 476 of the Companies Act 2006.

The director acknowledges his responsibilities for:
(a)ensuring that the company keeps accounting records which comply with Sections 386 and 387 of the Companies Act 2006 and
(b)preparing financial statements which give a true and fair view of the state of affairs of the company as at the end of each financial year and of its profit or loss for each financial year in accordance with the requirements of Sections 394 and 395 and which otherwise comply with the requirements of the Companies Act 2006 relating to financial statements, so far as applicable to the company.

NOVA HEALTH (HOLDINGS) LTD (REGISTERED NUMBER: 09433053)

Statement of Financial Position - continued
30 April 2024


The financial statements have been prepared and delivered in accordance with the provisions applicable to companies subject to the small companies regime.

In accordance with Section 444 of the Companies Act 2006, the Statement of Comprehensive Income has not been delivered.

The financial statements were approved by the director and authorised for issue on 19 September 2024 and were signed by:





Yasirali Pirmohamed - Director


NOVA HEALTH (HOLDINGS) LTD (REGISTERED NUMBER: 09433053)

Notes to the Financial Statements
for the Year Ended 30 April 2024

1. STATUTORY INFORMATION

Nova Health (Holdings) Ltd is a private company, limited by shares , registered in England and Wales. The company's registered number and registered office address can be found on the Company Information page.

2. ACCOUNTING POLICIES

Basis of preparing the financial statements
These financial statements have been prepared in accordance with Financial Reporting Standard 102 "The Financial Reporting Standard applicable in the UK and Republic of Ireland" including the provisions of Section 1A "Small Entities" and the Companies Act 2006. The financial statements have been prepared under the historical cost convention.

Preparation of consolidated financial statements
The financial statements contain information about Nova Health (Holdings) Ltd as an individual company and do not contain consolidated financial information as the parent of a group. The company is exempt under Section 399(2A) of the Companies Act 2006 from the requirements to prepare consolidated financial statements.

Turnover
Turnover is measured at the fair value of the consideration received or receivable, excluding discounts, rebates, value added tax and other sales taxes.

Investments in subsidiaries
Investments in subsidiary undertakings are recognised at cost.

Taxation
Taxation for the year comprises current and deferred tax. Tax is recognised in the Income Statement, except to the extent that it relates to items recognised in other comprehensive income or directly in equity.

Current or deferred taxation assets and liabilities are not discounted.

Current tax is recognised at the amount of tax payable using the tax rates and laws that have been enacted or substantively enacted by the statement of financial position date.

Deferred tax
Deferred tax is recognised in respect of all timing differences that have originated but not reversed at the statement of financial position date.

Timing differences arise from the inclusion of income and expenses in tax assessments in periods different from those in which they are recognised in financial statements. Deferred tax is measured using tax rates and laws that have been enacted or substantively enacted by the year end and that are expected to apply to the reversal of the timing difference.

Unrelieved tax losses and other deferred tax assets are recognised only to the extent that it is probable that they will be recovered against the reversal of deferred tax liabilities or other future taxable profits.

3. EMPLOYEES AND DIRECTORS

The average number of employees during the year was NIL (2023 - NIL).

NOVA HEALTH (HOLDINGS) LTD (REGISTERED NUMBER: 09433053)

Notes to the Financial Statements - continued
for the Year Ended 30 April 2024

4. FIXED ASSET INVESTMENTS
Shares in
group
undertaking
£   
COST
At 1 May 2023
and 30 April 2024 622,916
NET BOOK VALUE
At 30 April 2024 622,916
At 30 April 2023 622,916

The company's investments at the Statement of Financial Position date in the share capital of companies include the following:

Long Eaton Healthcare Ltd
Registered office: United Kingdom
Nature of business: Pharmacy
%
Class of shares: holding
Ordinary 100.00
2024 2023
£    £   
Aggregate capital and reserves 202,486 190,469
Profit for the year 84,568 65,146

5. CREDITORS: AMOUNTS FALLING DUE WITHIN ONE YEAR
2024 2023
£    £   
Bank loans and overdrafts (see note 7) 30,105 30,110
Amounts owed to group undertakings 142,957 83,618
Tax 1,668 4,103
Directors' current accounts 103,160 142,160
Accrued expenses 480 480
278,370 260,471

6. CREDITORS: AMOUNTS FALLING DUE AFTER MORE THAN ONE
YEAR
2024 2023
£    £   
Bank loans (see note 7) 248,975 285,323

Amounts falling due in more than five years:

Repayable by instalments
Bank loans more 5 yr by instal 128,553 164,901

NOVA HEALTH (HOLDINGS) LTD (REGISTERED NUMBER: 09433053)

Notes to the Financial Statements - continued
for the Year Ended 30 April 2024

7. LOANS

An analysis of the maturity of loans is given below:

2024 2023
£    £   
Amounts falling due within one year or on demand:
Bank overdrafts - 5
Bank loans 30,105 30,105
30,105 30,110

Amounts falling due between one and two years:
Bank loans - 1-2 years 30,105 30,105

Amounts falling due between two and five years:
Bank loans - 2-5 years 90,317 90,317

Amounts falling due in more than five years:

Repayable by instalments
Bank loans more 5 yr by instal 128,553 164,901

8. SECURED DEBTS

The following secured debts are included within creditors:

2024 2023
£    £   
Bank loans 279,080 315,428

9. CALLED UP SHARE CAPITAL

Allotted, issued and fully paid:
Number: Class: Nominal 2024 2023
value: £    £   
1 Ordinary A 1 1 1
1 Ordinary B 1 1 1
2 2

Each share has one voting right and equal rights to dividends and distributions.

NOVA HEALTH (HOLDINGS) LTD (REGISTERED NUMBER: 09433053)

Notes to the Financial Statements - continued
for the Year Ended 30 April 2024

10. RESERVES
Retained
earnings
£   

At 1 May 2023 77,121
Profit for the year 55,516
Dividends (37,000 )
At 30 April 2024 95,637

11. RELATED PARTY DISCLOSURES

During the year, the company received management income of £30,000 from its subsidiary company, Long Eaton Healthcare Ltd which is registered in England under company number 07981419.

12. ULTIMATE CONTROLLING PARTY

The company is controlled by Mr and Mrs Pirmohamed.